02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
22:03 , Jan 4, 2019 |  BC Week In Review  |  Company News

Novartis shares data on discontinued antibiotic research

Novartis AG (NYSE:NVS; SIX:NOVN) has included data from three discontinued antibacterial programs on a public data resource, the Shared Platform for Antibiotic Research and Knowledge (SPARK). SPARK is managed by The Pew Charitable Trusts, an...
22:52 , Jan 3, 2019 |  BC Extra  |  Company News

Novartis shares data on discontinued antibiotic research

Novartis AG (NYSE:NVS; SIX:NOVN) has included data from three discontinued antibacterial programs on a public data resource, the Shared Platform for Antibiotic Research and Knowledge (SPARK). SPARK is managed by The Pew Charitable Trusts, an...
16:59 , Oct 26, 2018 |  BC Week In Review  |  Company News

Achaogen furnishes data for Pew antibiotic platform targeting Gram-negative bacteria

Achaogen Inc. (NASDAQ:AKAO) gave data from a discontinued program to The Pew Charitable Trusts' Shared Platform for Antibiotic Research and Knowledge (SPARK), an open-access platform launched last month. Pew Senior Officer Wes Kim told BioCentury...
15:16 , Oct 26, 2018 |  BioCentury  |  Regulation

Learning the limits of limited use

While it’s too soon to tell if FDA’s limited-use pathway for anti-infectives will boost development in the underserved field, the pathway’s first approval has helped clarify the amount of uncertainty the agency is willing to...
15:00 , Oct 22, 2018 |  BC Extra  |  Company News

Achaogen furnishes data for Pew antibiotic platform targeting Gram-negative bacteria

Achaogen Inc. (NASDAQ:AKAO) gave data from a discontinued program to The Pew Charitable Trusts' Shared Platform for Antibiotic Research and Knowledge (SPARK), an open-access platform launched last month. Pew Senior Officer Wes Kim told BioCentury...
20:07 , Oct 11, 2018 |  BC Extra  |  Company News

Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair

Cancer company VisionGate Inc. (Phoenix, Ariz.) hired John Glasspool as chief operating and strategy officer, a newly created position. He was EVP and head of corporate strategy and customer operations at Baxalta Inc., which Shire...
21:52 , Sep 18, 2018 |  BC Extra  |  Company News

Management tracks: BioTime, Immune-Onc

Degenerative disease company BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX) named Brian Culley CEO, to replace co-CEOs Adi Mohanty and Michael West. Most recently, Culley was CEO of infectious disease company Artemis Therapeutics Inc. (OTCQB:ATMS). Immunotherapy company...
17:50 , Sep 14, 2018 |  BC Extra  |  Politics & Policy

Gottlieb releases FDA's plan to combat antibiotic resistance, calls for funding

FDA Commissioner Scott Gottlieb reiterated the call for new funding mechanisms to combat antimicrobial resistance during remarks made at a Pew Charitable Trusts meeting Friday. Gottlieb also revealed FDA's 2019 strategic plan to address AMR,...
22:19 , Jul 19, 2018 |  BC Innovations  |  Translation in Brief

Public Funding Highlights: 2Q18

Public Funding Highlights: 2Q18 Selected developments and initiatives in 2Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI) and the...